Group 1 - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is recognized as a mid-cap stock to buy, with Truist Securities raising its price target to $230 from $220 while maintaining a Buy rating [1] - The increase in price target is attributed to positive results from the HERIZON-GEA trial, leading to higher estimations for Ziihera [1][3] - Jazz Pharmaceuticals plans to file a supplemental Biologics License Application (sBLA) in the first half of 2026 to obtain a broad label for first-line gastroesophageal adenocarcinoma (GEA) as both doublet and triplet therapy [2] Group 2 - Truist Securities expects strong commercial adoption of Jazz Pharmaceuticals' products following clearance based on clinical data, with over 90% prescriber crossover between GEA and biliary tract cancer (BTC) [3] - The company develops treatments for serious illnesses, with key products including Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos [3]

While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initiated its adjusted earnings and net sales guidance for the full-year 2026.For fiscal 2026, Merck now projects adjusted earnings in a range of $5.00 to $5.15 per share on sales between $65.5 billion and $67.0 billion.On average, analysts polled expect the company to report earnings of $5.63 per share on sales of $67.58 billion for the year. Ana ...

Core Viewpoint - Pyxis Oncology, Inc. is undergoing a leadership transition with the appointment of Thomas Civik as Interim CEO, following the departure of Lara S. Sullivan, to ensure continuity in advancing the company's strategic and clinical goals [1][2][3]. Leadership Transition - Thomas Civik, a long-time member of the Board of Directors and an experienced biotechnology executive, has been appointed as Interim Chief Executive Officer [2][4]. - Lara S. Sullivan has stepped down from her roles as President, CEO, and Chief Medical Officer after six years of leadership [2][4]. - The Board of Directors is conducting a structured search for a permanent CEO while maintaining operational continuity through the established clinical development leadership team [3][4]. Company Focus and Clinical Programs - Pyxis Oncology's lead program, micvotabart pelidotin (MICVO), is currently in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and a Phase 1/2 study in combination with Merck's pembrolizumab [4][8]. - The company aims to prioritize the execution of its clinical programs and upcoming milestones, focusing on improving patient outcomes in difficult-to-treat cancers [5][8]. Background of Interim CEO - Thomas Civik previously served as President and CEO of Five Prime Therapeutics, leading its acquisition by Amgen for $1.9 billion in April 2021 [5][6]. - He has extensive experience in oncology development, having held leadership roles at Genentech for 17 years, overseeing key therapies such as Avastin and Tecentriq [6]. About Pyxis Oncology - Pyxis Oncology is a clinical-stage biopharmaceutical company focused on developing therapeutics for difficult-to-treat cancers, with MICVO being a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin [7][10]. - MICVO is designed to treat solid tumors through a multi-pronged mechanism of action, including direct tumor cell killing and mobilizing an anti-tumor immune response [10].

Incyte Corp (NASDAQ:INCY) is one of the most undervalued stocks to buy and hold for 5 years. On January 27, Bank of America Securities analyst Tazeen Ahmad assigned a Buy rating to Incyte and set a $118 price target. This bullish ratings action stands in contrast to Wells Fargo’s downgrade of Incyte Corp (NASDAQ:INCY) to Equal Weight from Overweight on January 20. According to Wells Fargo, which also lowered the stock’s price target to $107 from $116, the downgrade reflects the company’s current valuation a ...

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 on January 13, maintaining an Outperform rating on the company’s shares. The firm cited substantial pipeline flexibility in 2026 as the key justification for the higher target. Pixabay/Public Domain Leerink decreased its fourth-quarter 2025 earnings per share forecast by 29%, from $1.65 to $1.19, citing exp ...

Core Viewpoint - AstraZeneca PLC (NASDAQ:AZN) is enhancing its weight management portfolio through a strategic collaboration with CSPC Pharmaceuticals to develop next-generation therapies for obesity and type 2 diabetes across eight programs [1][2]. Group 1: Collaboration Details - The agreement includes the initial progress of four programs, utilizing CSPC's AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing technology [2]. - AstraZeneca will gain exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, which features one clinical-ready asset, SYH2082, and three preclinical programs [2]. Group 2: Existing Portfolio - The collaboration complements AstraZeneca's existing weight management portfolio, which includes a range of next-generation treatments targeting obesity and related complications [3]. - Current treatments in the pipeline include elecoglipron (AZD5004), AZD9550, and AZD6234, along with several preclinical assets [3]. Group 3: Company Overview - AstraZeneca PLC is a biopharmaceutical company engaged in the exploration, development, manufacturing, and commercialization of prescription medicines [4]. - The company distributes its products through local representative offices and distributors [4].

Core Viewpoint - The article discusses the promising results of fecal microbiota transplantation (FMT) combined with immunotherapy in treating non-small cell lung cancer (NSCLC), melanoma, and metastatic renal cell carcinoma (mRCC), highlighting its potential to overcome resistance to PD-1 therapy and improve patient outcomes [2][3][4]. Group 1: FMT and Immunotherapy in NSCLC and Melanoma - The FMT-LUMINate trial demonstrated an objective response rate (ORR) of 80% (16/20) in NSCLC and 75% (15/20) in melanoma, achieving the primary endpoint [8]. - Safety assessments indicated no grade 3 or higher adverse events in the NSCLC cohort, while 65% of melanoma patients experienced grade 3 or higher adverse events [8]. - The study found that responders had a unique gut microbiome composition post-FMT, with significant reductions in specific bacterial species associated with non-responders [9]. Group 2: FMT in Metastatic Renal Cell Carcinoma - The PERFORM trial showed that 50% (10/20) of mRCC patients experienced grade 3 immune-related adverse events, with no severe FMT-related toxicities reported [11][14]. - The objective response rate was 50% (9/18), including 11% (2/18) achieving complete response, with most responders not experiencing severe immune-related adverse events [14]. - Improvements in gut microbiome diversity were linked to reduced toxicity and enhanced treatment response, while the presence of specific bacteria correlated with higher immune-related adverse events [15][16]. Group 3: FMT Combined with Pembrolizumab and Axitinib - The TACITO trial evaluated the efficacy of donor-derived FMT in mRCC patients receiving pembrolizumab and axitinib, with a primary endpoint of disease progression-free survival [18][21]. - Although the primary endpoint was not met, the donor FMT group showed a significantly longer median progression-free survival of 24.0 months compared to 9.0 months in the placebo group [22]. - The donor FMT group had an ORR of 52%, while the placebo group had 32%, indicating potential benefits of selective donor FMT in enhancing immunotherapy outcomes [22].

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the implementation of an equity line with IRIS, known as "SmartATM® " for a maximum amount of €5 million over five years (terms set out in the Appendix without this. ...

Core Insights - Addex Therapeutics announced the publication of data in *Molecular Psychiatry* indicating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) could significantly improve treatment for anxiety and fear-related disorders, including PTSD [2][3] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [9] - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury [9] - Addex has a 20% equity interest in Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including mGlu7 NAM for mood disorders [9] Research Findings - The study conducted by scientists from the Center for Psychiatric Neurosciences demonstrated that ADX71743, a selective mGlu7 NAM, can disrupt the reconsolidation of fear memories, which is a critical process in the treatment of anxiety and trauma-related conditions [3][4] - Administration of ADX71743 in rat models showed a significant decrease in the reinstatement of fear, indicating its potential as a therapeutic intervention [4][5] - Electrophysiological analyses revealed that ADX71743 modulated glutamatergic transmission at thalamus-to-amygdala synapses, which are essential for fear learning, providing mechanistic support for its effects [5][6] Market Context - Anxiety and stress-related disorders are among the most prevalent neuropsychiatric conditions globally, with many patients experiencing inadequate responses to existing therapies [4] - Current treatments often target symptoms and require continuous use, leading to risks of tolerance and dependence, highlighting the need for innovative therapeutic approaches [4][6] Future Implications - The research suggests that targeting memory reconsolidation with mGlu7 NAMs could offer a time-limited pharmacological intervention, potentially providing a more durable solution for pathological fear compared to continuous symptom-suppressing medications [6] - The findings support the long-term belief of Addex in the differentiated mechanism of targeting mGlu7 for treating anxiety and fear-related disorders [4][6]

Core Insights - Pharming Group N.V. has announced its financial guidance for 2026, projecting total revenues between US$405 million and US$425 million, representing an 8% to 13% growth [3][7][8] - The company will highlight its advancing clinical-stage pipeline, focusing on two major programs targeting primary immunodeficiencies and mitochondrial diseases during its Investor Day [2][4][6] Financial Guidance - Total revenue guidance for 2026 is set between US$405 million and US$425 million, driven by growth in its commercial products [3][8] - Total operating expenses are expected to be between US$330 million and US$335 million, primarily due to increased R&D expenses related to ongoing clinical trials [7][8] Pipeline Overview - Leniolisib is being developed for primary immunodeficiencies with immune dysregulation, with ongoing Phase II trials expected to yield top-line data in the second half of 2026 [4][5] - Napazimone (KL1333) is being developed for mtDNA-driven mitochondrial disease, with a pivotal clinical trial ongoing and results anticipated in 2027 [6][9] Clinical Programs - Leniolisib is currently approved as Joenja in the U.S. and is the first targeted treatment for activated PI3Kδ syndrome, with potential applicability across broader patient populations [5][6] - Napazimone (KL1333) aims to become the first standard of care for mtDNA-driven mitochondrial disease, addressing significant unmet medical needs [6][9] Investor Day Details - The Investor Day will feature presentations from clinical experts discussing disease biology and the potential impact of Pharming's programs [10][16] - The event is scheduled for February 3, 2026, from 10:00 a.m. to 12:00 p.m. EST, and will be available via webcast [11]